The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers

International Journal of Cancer

Volumn 136, Issue 4, 2015, Pages 844-853

  Vedeld, Hege Marie ^a,b,c   Andresen, Kim ^a,b   Eilertsen, Ina Andrassy ^a,b   Nesbakken, Arild ^b,d   Seruca, Raquel ^e   Gladhaug, Ivar P ^b,f   Thiis Evensen, Espen ^g   Rognum, Torleiv O ^b,h   Boberg, Kirsten Muri ^a,b,g   Lind, Guro E ^a,b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d AKER UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF PORTO   (Portugal)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g Section of Gastroenterology   (Norway)

^h NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Biomarker; Cancer; CDO1; DCLK1; DNA methylation; SFRP1; ZNF331; ZSCAN18

Indexed keywords

BIOLOGICAL MARKER; CYSTEINE DIOXYGENASE; CYSTEINE DIOXYGENASE, TYPE I, HUMAN; DNA BINDING PROTEIN; TUMOR MARKER; TUMOR PROTEIN; ZINC FINGER AND SCAN DOMAIN CONTAINING 18 PROTEIN, HUMAN; ZNF331 PROTEIN, HUMAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; CDO1 GENE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; DCLK1 GENE; DISEASE ASSOCIATION; DNA METHYLATION; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; NORWAY; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SFRP1 GENE; STOMACH CANCER; ZNF331 GENE; ZSCAN18 GENE; BILE DUCT TUMOR; CASE CONTROL STUDY; COLORECTAL TUMOR; DNA SEQUENCE; GENETICS; INTRAHEPATIC BILE DUCT; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PROMOTER REGION; STOMACH TUMOR; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; CYSTEINE DIOXYGENASE; DNA METHYLATION; DNA-BINDING PROTEINS; GENE EXPRESSION; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; ROC CURVE; SEQUENCE ANALYSIS, DNA; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84918780619     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29039     Document Type: Article

References (46)

1. Siegel R, Nakamura T, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
3. American Cancer Society. Global cancer facts & figures, 2nd edn. Atlanta: American Cancer Society, 2011
4. Blechacz B, Gores GJ. Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment. Hepatology 2008;48:308-21
5. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011;25:1010-22
6. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92
7. Schuebel KE, Chen W, Cope L, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007;3: 1709-23
8. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-A mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-16
9. Ned RM, Melillo S, Marrone M. Fecal DNA testing for colorectal cancer screening: The ColoSure test. PLoS Curr 2011;3:RRN1220
10. Shin SH, Lee K, Kim BH, et al. Bile-based detection of extrahepatic cholangiocarcinoma with quantitative DNA methylation markers and its high sensitivity. J Mol Diagn 2012;14: 256-63
11. Nagasaka T, Tanaka N, Cullings HM, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst 2009;101: 1244-58
12. Tanzer M, Balluff B, Distler J, et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One 2010;5:e9061
13. Costa VL, Henrique R, Danielsen SA, et al. Three epigenetic biomarkers, GDF15, TMEFF2 and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 2010;16:5842-51
14. Myllykangas S, Bohling T, Knuutila S. Specificity, selection and significance of gene amplifications in cancer. Semin Cancer Biol 2007;17:42-55
15. Myllykangas S, Himberg J, Bohling T, et al. DNA copy number amplification profiling of human neoplasms. Oncogene 2006;25:7324-32
16. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499: 214-18
17. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9
18. Suzuki H, Tokino T, Shinomura Y, et al. DNA methylation and cancer pathways in gastrointestinal tumors. Pharmacogenomics 2008;9:1917-28
19. Fernandes MS, Carneiro F, Oliveira C, et al. Colorectal cancer and RASSF family-A special emphasis on RASSF1A. Int J Cancer 2013;132: 251-8
20. Moinova H, Leidner RS, Ravi L, et al. Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies. Cancer Epidemiol Biomarkers Prev 2012;21:594-600
21. Lind GE, Ahmed D, Lothe RA. Vimentin in upper gastrointestinal pathologies-letter. Cancer Epidemiol Biomarkers Prev 2012;21:1889
22. Andresen K, Boberg KM, Vedeld HM, et al. Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. Epigenetics 2012;7:1249-57
23. Thiis-Evensen E, Hoff GS, Sauar J, et al. Population- based surveillance by colonoscopy: Effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 1999;34:414-20
24. Sveen A, Agesen TH, Nesbakken A, et al. Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. Genome Med 2011;3:32
25. Agesen TH, Sveen A, Merok MA, et al. ColoGuideEx: A robust gene classifier specific for stage II colorectal cancer prognosis. Gut 2012;61:1560-7
26. Sveen A, Agesen TH, Nesbakken A, et al. Colo- GuidePro: A prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin Cancer Res 2012;18:6001-10
27. Vedeld HM, Skotheim RI, Lothe RA, et al. The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer. Epigenetics 2014;9:346-50
28. Lind GE, Ahlquist T, Kolberg M, et al. Hypermethylated MAL gene-A silent marker of early colon tumorigenesis. J Transl Med 2008;6:13
29. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 1999;59:3730-40
30. Lind GE, Danielsen SA, Ahlquist T, et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer 2011;10:85
31. Weisenberger DJ, Campan M, Long TI, et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005;33: 6823-36
32. Caldwell GM, Jones C, Gensberg K, et al. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 2004;64:883-8
33. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002;3:101-28
34. Dulak AM, Schumacher SE, van LJ, et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012;72:4383-93
35. Brait M, Ling S, Nagpal JK, et al. Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers. PLoS One 2012;7:e44951
36. Taniguchi H, Yamamoto H, Hirata T, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005;24:7946-52
37. Ebert MP, Model F, Mooney S, et al. Aristalesslike homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology 2006;131:1418-30
38. Ludyga N, Grunwald B, Azimzadeh O, et al. Nucleic acids from long-term preserved FFPE tissues are suitable for downstream analyses. Virchows Arch 2012;460:131-40
39. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31: 141-9
40. Karpinski P, Sasiadek MM, Blin N. Aberrant epigenetic patterns in the etiology of gastrointestinal cancers. J Appl Genet 2008;49:1-10
41. Sriraksa R, Zeller C, El-Bahrawy MA, et al. CpG-island methylation study of liver fluke-related cholangiocarcinoma. Br J Cancer 2011;104:1313-18
42. Lothe RA, Ahmed D, Andresen K, et al. Methods and biomarkers for detection of gastrointestinal cancers. US provisional application filed 61/451,198, INVEN-31899/US-1/PRO, 2011
43. De Carvalho DD, Sharma S, You JS, et al. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 2012; 21:655-67
44. Nakanishi Y, Seno H, Fukuoka A, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat Genet 2013;45: 98-103
45. Yu J, Liang QY, Wang J, et al. Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer. Oncogene 2012;32:307-17
46. Morris MR, Ricketts CJ, Gentle D, et al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 2011; 30:1390-401.